Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Highlights•AML is a highly heterogeneous disease and warrants an individualized
approach.•The advent of effective low-intensity regimens has improved outcomes in older …

The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently
transforming acute myeloid leukemia (AML) therapy. However, there is a lack of clinically …

Risk stratification in acute myeloid leukemia (AML) remains principle in survival
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …

This phase 1b trial (NCT02670044) evaluated venetoclax-idasanutlin in patients with
relapsed/refractory (R/R) acute myeloid leukemia (AML) ineligible for cytotoxic …

CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for
acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized …

Background Venetoclax combined with intensive chemotherapy has been shown to be safe
with promising activity in fit patients with newly diagnosed acute myeloid leukaemia. The aim …

Acute myeloid leukemia (AML) can be treated with either high-or low-intensity regimens.
Highly sensitive assays for measurable residual disease (MRD) now allow for a more …

The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia
(AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment …

Venetoclax+ hypomethylating agent (Ven‐HMA) is currently the standard frontline therapy
for older/unfit patients with newly diagnosed acute myeloid leukemia (ND‐AML). Our …